|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2008
Pulmonary hypertension in COPD
1 Dept for Respiratory Diseases and Respiratory Intensive Care, Centre Hospitalier Universitaire de Nancy, Vandoeuvre-les-Nancy and 3 Dept of Pneumology, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France, and 3 Dept of Pathophysiology, Erasme Campus, Brussels, Belgium.
CORRESPONDENCE: A. Chaouat, Service des Maladies Respiratoires et Réanimation Respiratoire, Hôpital de Brabois, Allée du Morvan, 54511 Vandoeuvre-lès-Nancy Cedex, France. Fax: 33 383154023. E-mail: a.chaouat{at}chu-nancy.fr
Keywords: Chronic obstructive pulmonary disease, hypoxaemia, inflammation, oxygen therapy, pulmonary hypertension, vasodilator agents
Received: February 1, 2008
Accepted May 29, 2008
Mild-to-moderate pulmonary hypertension is a common complication of chronic obstructive pulmonary disease (COPD); such a complication is associated with increased risks of exacerbation and decreased survival. Pulmonary hypertension usually worsens during exercise, sleep and exacerbation. Pulmonary vascular remodelling in COPD is the main cause of increase in pulmonary artery pressure and is thought to result from the combined effects of hypoxia, inflammation and loss of capillaries in severe emphysema.
A small proportion of COPD patients may present with "out-of-proportion" pulmonary hypertension, defined by a mean pulmonary artery pressure >35–40 mmHg (normal is no more than 20 mmHg) and a relatively preserved lung function (with low to normal arterial carbon dioxide tension) that cannot explain prominent dyspnoea and fatigue. The prevalence of out-of-proportion pulmonary hypertension in COPD is estimated to be very close to the prevalence of idiopathic pulmonary arterial hypertension.
Cor pulmonale, defined as right ventricular hypertrophy and dilatation secondary to pulmonary hypertension caused by respiratory disorders, is common. More studies are needed to define the contribution of cor pulmonale to decreased exercise capacity in COPD. These studies should include improved imaging techniques and biomarkers, such as the B-type natriuretic peptide and exercise testing protocols with gas exchange measurements.
The effects of drugs used in pulmonary arterial hypertension should be tested in chronic obstructive pulmonary disease patients with severe pulmonary hypertension. In the meantime, the treatment of cor pulmonale in chronic obstructive pulmonary disease continues to rest on supplemental oxygen and a variety of measures aimed at the relief of airway obstruction.
This article has been cited by other articles:
|
|
 |
|
  S. M. Wilson, P. Shen, C. F. Rider, S. L. Traves, D. Proud, R. Newton, and M. A. Giembycz Selective Prostacyclin Receptor Agonism Augments Glucocorticoid-Induced Gene Expression in Human Bronchial Epithelial Cells J. Immunol., November 15, 2009; 183(10): 6788 - 6799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Hoeper The new definition of pulmonary hypertension Eur. Respir. J., October 1, 2009; 34(4): 790 - 791. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Churg and J. L. Wright Testing Drugs in Animal Models of Cigarette Smoke-induced Chronic Obstructive Pulmonary Disease Proceedings of the ATS, September 15, 2009; 6(6): 550 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chaouat, L. Savale, C. Chouaid, L. Tu, B. Sztrymf, M. Canuet, B. Maitre, B. Housset, C. Brandt, P. Le Corvoisier, et al. Role for Interleukin-6 in COPD-Related Pulmonary Hypertension Chest, September 1, 2009; 136(3): 678 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gur, P. J. Kadowitz, S. Thammasitboon, J. A. Lasky, and W. J. G. Hellstrom Characterization of Erectile Function in Monocrotaline-Treated Pulmonary Hypertensive Rats J Androl, September 1, 2009; 30(5): 495 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Weitzenblum and A Chaouat Cor pulmonale Chronic Respiratory Disease, August 1, 2009; 6(3): 177 - 185. [Abstract] [PDF]
|
|
|
|
|
|
M. W. Sims, D. J. Margolis, A. R. Localio, R. A. Panettieri, S. M. Kawut, and J. D. Christie Impact of Pulmonary Artery Pressure on Exercise Function in Severe COPD Chest, August 1, 2009; 136(2): 412 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Hoeper, J. A. Barbera, R. N. Channick, P. M. Hassoun, I. M. Lang, A. Manes, F. J. Martinez, R. Naeije, H. Olschewski, J. Pepke-Zaba, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S85 - S96. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Humbert Update in Pulmonary Hypertension 2008 Am. J. Respir. Crit. Care Med., April 15, 2009; 179(8): 650 - 656. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |